Background/Aims: The insulin-like growth factor (IGF) system has been implicated in tumor growth, invasion, and metastasis. However, reports on the IGF-1 receptor (IGF-1R) based on radioimmunoassays are conflicting, and its prognostic implications in non-small-cell lung cancer (NSCLC) are still controversial.
INTRODUCTION
Non-small-cell lung cancer (NSCLC) accounts for approximately 75～80% of all lung cancers and is the leading cause of cancer-related deaths worldwide 1) . However, 20% of stage I and 30% of stage II NSCLC patients who are treated with curative intent experience recurrence of their cancer, which is often incurable at the time of discovery. This statistic indicates the urgent need to elucidate the carcinogenesis of lung cancer and to devise new approaches for its prevention and treatment, such as chemoprevention.
The insulin-like growth factor (IGF) system plays a critical role in the growth and development of many tissues and regulates overall growth, particularly prenatal growth. It has also been implicated in various pathophysiological conditions and is thought to play a prominent role in tumorigenesis. The insulinlike growth factor-1 receptor (IGF-1R) is a glycosylated heterotetramer composed of two extracellular α-and β -subunits that have intrinsic tyrosine kinase activity, and it shares 70% homology with the insulin receptor. It is encoded by the IGF-1R gene located on chromosome 15q26 2, 3) . IGF-1R mainly mediates the effect of IGFs, which are potent mitogens that regulate cell proliferation, differentiation, and protection from apoptosis 4) . Clinical and epidemiological data suggest that the serum levels of IGF-1 and IGF-binding proteins (IGFBPs) are related to the risk of solid tumors, such as breast, prostate, endometrial, ovarian, and colon cancer 5) . In breast cancer, IGF-1R expression and activation have been linked to disease progression, increased resistance to radiotherapy, and a poor prognosis 6, 7) . The expression of a dominant-negative truncated IGF-1R in colon cancer cells reduced the expression of vascular endothelial growth factor, impaired tumor progression in nude mice, and increased tumor cell apoptosis 8) . More focused studies of IGF-1R expression in the breast and prostate that used immunohistochemistry or matched cell lines corresponding to normal and tumor tissue revealed that normal epithelium and early-stage tumors both express abundant IGF-1R and that its expression is reduced significantly in advanced metastatic cancer [9] [10] [11] [12] [13] .
Although several commercial anti-IGF-1R antibodies are available, no scoring system for IGF-1R expression in formalin-fixed, paraffin-embedded tissue has been established. Here, we report the prognostic implications of IGF-1R expression as determined immunohistochemically using archived materials of stage I NSCLC. We evaluated its expression in cancer cell membranes and the cytoplasm and correlated its expression with various clinicopathological parameters.
MATERIAL AND METHODS

Study population and samples
We examined 71 tissue specimens from stage I NSCLC patients who had undergone curative surgical removal of primary lesions between 1995 and 1998 at Yonsei Medical Center. The pathological evaluation established the histological classification and stage in all patients. None of the patients had either radiotherapy or chemotherapy before or after surgery until the disease recurred. All clinical and pathological information and follow-up data were obtained from reports from our registry service. The study was reviewed and approved by the institution's Surveillance Committee to allow us to obtain pertinent information from the patients' files.
Immunohistochemical staining for IGF-1R
Paraffin-embedded, 4-µm-thick tissue sections were stained with mouse monoclonal antibody against human IGF-1R (BioSource International, Camarillo, CA, USA). The sections were deparaffinized in a xylene bath, rehydrated using a graded alcohol series, and retrieved in 10 mM sodium citrate buffer via microwave heating for 15 min at 95℃. The sections were then treated with 0.3% hydrogen peroxidase for 10 min to block endogenous peroxidase activity. Subsequently, the sections were incubated with the primary anti-IGF-1R antibody (1:50) for 30 min at room temperature and processed using standard avidin-biotin immunohistochemical techniques according to the manufacturer's recommendations (Vector Laboratories, Burlingame, CA, USA). Diaminobenzidine (DAB) was used as a chromogen, and commercial hematoxylin was used for counterstaining. Each time, placenta and breast cancer tissues were stained to serve as positive controls. Adjacent normal-appearing bronchial epithelium within each tissue section served as an internal reference. The intensity of IGF-1R immunostaining of the membrane and cytoplasm of the invasive cancer components was evaluated. Cell membrane and cytoplasm staining were scored on a scale of 0, 1+, 2+, and 3+, where scores of 1+ and above were classified as positive. All slides were evaluated and scored independently by two pathologists who were blind to the subjects' clinical information.
Statistical analysis
In the univariate analysis, independent sample t-tests and Fisher's exact tests were used for continuous and categorical variables, respectively. The Kaplan-Meier estimator was used to compute survival probability as a function of time. The log-rank test was used to compare survival time between groups. All statistical tests were two-sided. p<0.05 was considered significant.
RESULTS
Patient demographic characteristics
The NSCLC cases included 51 (71.8%) males and 20 (28.2%) females with a median age of 61.8 (31-83) years, which is similar to the distribution in the large database of patients with stage I NSCLC from our institution (data not shown). Thirty-five (49.3%) patients were diagnosed with adenocarcinoma, 33 (46.5%) with squamous cell carcinoma, and three (4.2%) with other histological subtypes. Fifty-eight (81.7%) patients had a history of smoking. The general clinical characteristics of the patients are shown in Table 1 .
IGF-1R immunohistochemistry
IGF-1R expression was granular, heterogeneous, and discrete, i.e., mainly localized to the cytoplasm of NSCLC cells ( Figure 1A and B). Some bronchioloalveolar carcinoma tissue showed distinct cytoplasmic IGF-1R expression (Fig. 1C) . However, the number of NSCLC tissues expressing IGF-1R was small. There were 62 (87.3%), seven (9.9%), two (2.8%), and zero (0.0%) NSCLC cases with IGF-1R staining scores of 0, 1+, 2+, and 3+, respectively. Cases with scores more than 1+ were defined as positive and were used for the subsequent statistical analysis. In the normal-appearing adjacent lung tissues, the cytoplasm of bronchial/bronchiolar epithelium showed uniform, constant IGF-1R expression. The immunohistochemical staining of IGF-1R in breast cancer and placenta tissues was also stable and reproducible (data not shown).
Correlation of IGF-1R expression with the clinicopathological parameters IGF-1R expression was positive in nine (12.7%) cases and negative in 62 (87.3%). IGF-1R expression was not associated with the clinical or pathological characteristics tested in this study ( Table 1 ). The overall survival curves did not differ significantly between the group of patients with tumors expressing IGF-1R and those with negative IGF-1R expression (Figure 2) . None of the patients with positive IGF-1R expression experienced distant metastasis or cancer-related death, although the difference did not reach significance (Table 1) .
DISCUSSION
IGFs are potent mitogens in several types of cancer, including NSCLC and small-cell lung cancer 15, 16) . Furthermore, IGF-1R can upregulate several aspects of the malignant phenotype and metastasis in vitro 17) . In breast cancer, IGF-1R expression and activation have been linked to disease progression, increased resistance to radiotherapy, and a poor prognosis 18, 19) . For lung cancer, no data are available on IGF-1R expression, so we focused on the expression of IGF-1R in patients with stage I NSCLC and its significance to the clinical outcome. We tested the prognostic significance of IGF-1R expression in formalin-fixed, paraffin-embedded tissues. We found that IGF-1R expression was downregulated in a significant fraction of patients with stage I NSCLC. Overall, nine of 71 tumors expressed IGF-1R, and its expression was localized to the membrane and cytoplasm, rather than the nucleus of NSCLC cells. Our data indicate that IGF-1R expression is not a prognostic factor in patients with stage I NSCLC. None of the patients expressing IGF-1R experienced distant metastasis or cancer-related death, although the difference was not significant. Our study did not show a better survival with IGF-1R expression. Other studies have shown that IGF-1R expression was significantly associated with a better survival in breast cancer and highly malignant soft tissue sarcoma 20, 21) , although other studies found the opposite 22, 23) .
Early studies showed that functionality of the IGF-1R was a prerequisite for neoplastic transformation and for survival of the transformed cell in vitro and in vivo 24) . More recent evidence has pointed to putative roles for IGF-1R in cell adhesion and cancer cell dedifferentiation 25) . The significant association with survival observed in this study is of particular relevance, and should be confirmed in additional cohorts of patients. In summary, in a homologous population of 71 patients with stage I NSCLC, we showed that IGF-1R expression is neither frequent nor a prognostic factor in stage I NSCLC. More comprehensive studies of the mechanism of IGF-1R expression in NSCLC are necessary to define the role of IGF-1R in lung carcinogenesis. 
